Every tumor is unique. Illumina next-generation sequencing (NGS) solutions can help you find the right approach, from single gene to comprehensive analysis, and go from insights to action.
Our TruSight Oncology 500 solution gives you pan-cancer coverage that was developed to align with key guidelines and evaluate DNA and RNA tumor biomarkers, including the immuno-oncology biomarkers tumor mutational burden (TMB) and microsatellite instability (MSI).
Illumina products and services facilitate cancer research by enabling the identification of genomic changes such as:
Illumina cancer research products support both NGS and microarray strategies for various study designs.
Illumina offers a wide variety of sequencing and microarray products for cancer research.
Find the optimal instrument and analysis software tools for your cancer research project.
Find a lab that provides demonstrated proficiency with Illumina next-generation sequencing systems to support genetic and genomic research, including cancer research.Find a Service Provider